CSIRO has come up with a new technique for repairing knee cartilage by combining chondrocytes with a biodegradable polymer.

A trial of a vaccine for stages II and III melanoma didn't turn out as expected, so the researchers tried it in stage IV patients, causing a few surprises.

The first merger of 2006 has created new opportunities in the hot field of theranostics. Ruth Beran talks with its architects about the merged company and its future plans.

To no one's surprise, CSL has become the dominant force in the Australian biotechnology sector. Graeme O'Neill learns from CSL's chief scientist, Andrew Cuthbertson, about the solid research that will drive the company in the next few years.

The research community is becoming more sophisticated in the way they approach intellectual property and industry partnerships. Ruth Beran looks at how technology transfer has changed, where it is going and the challenges it faces.

Biotechnology has provided a solution to the problem of how to get science to the market without compromising research, writes editor-in-chief Iain Scott.

Pfizer's Peter Corr told the AusBiotech 2005 conference that big pharma and biotech are part of a delicate ecosystem -- and both have key roles to play.

Kiran Mazumdar-Shaw told AusBiotech 2005 about opportunities for Australian biotech to work with India.

US venture capitalist Osagie Imasogie told AusBiotech 2005 that biotech companies need to get aggressive when it comes to finding opportunities.

Manipulating the genome before fertilisation could prove more successful that current technique used in animal transgenesis, Graeme O'Neill reports.